Research ExplorerPublicationsPelvic Lymphadenectomy in Vulvar Cancer - Does it make sense...

Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?

Standard

Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense? / Woelber, Linn; Bommert, Mareike; Prieske, Katharina; Fischer, Inger; Zu Eulenburg, Christine; Vettorazzi, Eik; Harter, Philipp; Jueckstock, Julia; Hilpert, Felix; de Gregorio, Niko; Iborra, Severine; Sehouli, Jalid; Ignatov, Atanas; Hillemanns, Peter; Fuerst, Sophie; Strauss, Hans-Georg; Baumann, Klaus; Beckmann, Matthias; Mustea, Alexander; Meier, Werner; Wimberger, Pauline; Hanker, Lars; Canzler, Ulrich; Fehm, Tanja; Luyten, Alexander; Hellriegel, Martin; Kosse, Jens; Heiss, Christoph; Hantschmann, Peer; Mallmann, Peter; Tanner, Berno; Pfisterer, Jacobus; Mahner, Sven; Schmalfeldt, Barbara; Jaeger, Anna.

In: GEBURTSH FRAUENHEILK, Vol. 80, No. 12, 12.2020, p. 1221-1228.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Woelber, L, Bommert, M, Prieske, K, Fischer, I, Zu Eulenburg, C, Vettorazzi, E, Harter, P, Jueckstock, J, Hilpert, F, de Gregorio, N, Iborra, S, Sehouli, J, Ignatov, A, Hillemanns, P, Fuerst, S, Strauss, H-G, Baumann, K, Beckmann, M, Mustea, A, Meier, W, Wimberger, P, Hanker, L, Canzler, U, Fehm, T, Luyten, A, Hellriegel, M, Kosse, J, Heiss, C, Hantschmann, P, Mallmann, P, Tanner, B, Pfisterer, J, Mahner, S, Schmalfeldt, B & Jaeger, A 2020, 'Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?', GEBURTSH FRAUENHEILK, vol. 80, no. 12, pp. 1221-1228. https://doi.org/10.1055/a-1120-0138

APA

Woelber, L., Bommert, M., Prieske, K., Fischer, I., Zu Eulenburg, C., Vettorazzi, E., Harter, P., Jueckstock, J., Hilpert, F., de Gregorio, N., Iborra, S., Sehouli, J., Ignatov, A., Hillemanns, P., Fuerst, S., Strauss, H-G., Baumann, K., Beckmann, M., Mustea, A., ... Jaeger, A. (2020). Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense? GEBURTSH FRAUENHEILK, 80(12), 1221-1228. https://doi.org/10.1055/a-1120-0138

Vancouver

Woelber L, Bommert M, Prieske K, Fischer I, Zu Eulenburg C, Vettorazzi E et al. Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense? GEBURTSH FRAUENHEILK. 2020 Dec;80(12):1221-1228. https://doi.org/10.1055/a-1120-0138

Bibtex

@article{9bcbe2a2d4284738a11b4e3a00bc5874,
title = "Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?",
abstract = "Since the publication of the updated German guideline in 2015, the recommendations for performing pelvic lymphadenectomy (LAE) in patients with vulvar cancer (VSCC) have changed considerably. The guideline recommends surgical lymph node staging in all patients with a higher risk of pelvic lymph node involvement. However, the current data do not allow the population at risk to be clearly defined, therefore, the indication for pelvic lymphadenectomy is still not clear. There are currently two published German patient populations who had pelvic LAE which can be used to investigate both the prognostic effect of histologically verified pelvic lymph node metastasis and the relation between inguinal and pelvic lymph node involvement. A total of 1618 patients with primary FIGO stage ≥ IB VSCC were included in the multicenter AGO CaRE-1 study (1998 - 2008), 70 of whom underwent pelvic LAE. During a retrospective single-center evaluation carried out at the University Medical Center Hamburg-Eppendorf (UKE), a total of 514 patients with primary VSCC treated between 1996 - 2018 were evaluated, 21 of whom underwent pelvic LAE. In both cohorts, around 80% of the patients who underwent pelvic LAE were inguinally node-positive, with a median number of three affected groin lymph nodes. There were no cases of pelvic lymph node metastasis without inguinal lymph node metastasis in either of the two cohorts. Between 33 - 35% of the inguinal node-positive patients also had pelvic lymph node metastasis; the median number of affected groin lymph nodes in these patients was high (> 4), and the maximum median diameter of the largest inguinal metastasis was > 40 mm in both cohorts. Pelvic lymph node staging and pelvic radiotherapy is therefore probably not necessary for the majority of node-positive patients with VSCC, as the relevant risk of pelvic lymph node involvement was primarily found in node-positive patients with high-grade disease. More, ideally prospective data collections are necessary to validate the relation between inguinal and pelvic lymph node involvement.",
author = "Linn Woelber and Mareike Bommert and Katharina Prieske and Inger Fischer and {Zu Eulenburg}, Christine and Eik Vettorazzi and Philipp Harter and Julia Jueckstock and Felix Hilpert and {de Gregorio}, Niko and Severine Iborra and Jalid Sehouli and Atanas Ignatov and Peter Hillemanns and Sophie Fuerst and Hans-Georg Strauss and Klaus Baumann and Matthias Beckmann and Alexander Mustea and Werner Meier and Pauline Wimberger and Lars Hanker and Ulrich Canzler and Tanja Fehm and Alexander Luyten and Martin Hellriegel and Jens Kosse and Christoph Heiss and Peer Hantschmann and Peter Mallmann and Berno Tanner and Jacobus Pfisterer and Sven Mahner and Barbara Schmalfeldt and Anna Jaeger",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).",
year = "2020",
month = dec,
doi = "10.1055/a-1120-0138",
language = "English",
volume = "80",
pages = "1221--1228",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "12",

}

RIS

TY - JOUR

T1 - Pelvic Lymphadenectomy in Vulvar Cancer - Does it make sense?

AU - Woelber, Linn

AU - Bommert, Mareike

AU - Prieske, Katharina

AU - Fischer, Inger

AU - Zu Eulenburg, Christine

AU - Vettorazzi, Eik

AU - Harter, Philipp

AU - Jueckstock, Julia

AU - Hilpert, Felix

AU - de Gregorio, Niko

AU - Iborra, Severine

AU - Sehouli, Jalid

AU - Ignatov, Atanas

AU - Hillemanns, Peter

AU - Fuerst, Sophie

AU - Strauss, Hans-Georg

AU - Baumann, Klaus

AU - Beckmann, Matthias

AU - Mustea, Alexander

AU - Meier, Werner

AU - Wimberger, Pauline

AU - Hanker, Lars

AU - Canzler, Ulrich

AU - Fehm, Tanja

AU - Luyten, Alexander

AU - Hellriegel, Martin

AU - Kosse, Jens

AU - Heiss, Christoph

AU - Hantschmann, Peer

AU - Mallmann, Peter

AU - Tanner, Berno

AU - Pfisterer, Jacobus

AU - Mahner, Sven

AU - Schmalfeldt, Barbara

AU - Jaeger, Anna

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

PY - 2020/12

Y1 - 2020/12

N2 - Since the publication of the updated German guideline in 2015, the recommendations for performing pelvic lymphadenectomy (LAE) in patients with vulvar cancer (VSCC) have changed considerably. The guideline recommends surgical lymph node staging in all patients with a higher risk of pelvic lymph node involvement. However, the current data do not allow the population at risk to be clearly defined, therefore, the indication for pelvic lymphadenectomy is still not clear. There are currently two published German patient populations who had pelvic LAE which can be used to investigate both the prognostic effect of histologically verified pelvic lymph node metastasis and the relation between inguinal and pelvic lymph node involvement. A total of 1618 patients with primary FIGO stage ≥ IB VSCC were included in the multicenter AGO CaRE-1 study (1998 - 2008), 70 of whom underwent pelvic LAE. During a retrospective single-center evaluation carried out at the University Medical Center Hamburg-Eppendorf (UKE), a total of 514 patients with primary VSCC treated between 1996 - 2018 were evaluated, 21 of whom underwent pelvic LAE. In both cohorts, around 80% of the patients who underwent pelvic LAE were inguinally node-positive, with a median number of three affected groin lymph nodes. There were no cases of pelvic lymph node metastasis without inguinal lymph node metastasis in either of the two cohorts. Between 33 - 35% of the inguinal node-positive patients also had pelvic lymph node metastasis; the median number of affected groin lymph nodes in these patients was high (> 4), and the maximum median diameter of the largest inguinal metastasis was > 40 mm in both cohorts. Pelvic lymph node staging and pelvic radiotherapy is therefore probably not necessary for the majority of node-positive patients with VSCC, as the relevant risk of pelvic lymph node involvement was primarily found in node-positive patients with high-grade disease. More, ideally prospective data collections are necessary to validate the relation between inguinal and pelvic lymph node involvement.

AB - Since the publication of the updated German guideline in 2015, the recommendations for performing pelvic lymphadenectomy (LAE) in patients with vulvar cancer (VSCC) have changed considerably. The guideline recommends surgical lymph node staging in all patients with a higher risk of pelvic lymph node involvement. However, the current data do not allow the population at risk to be clearly defined, therefore, the indication for pelvic lymphadenectomy is still not clear. There are currently two published German patient populations who had pelvic LAE which can be used to investigate both the prognostic effect of histologically verified pelvic lymph node metastasis and the relation between inguinal and pelvic lymph node involvement. A total of 1618 patients with primary FIGO stage ≥ IB VSCC were included in the multicenter AGO CaRE-1 study (1998 - 2008), 70 of whom underwent pelvic LAE. During a retrospective single-center evaluation carried out at the University Medical Center Hamburg-Eppendorf (UKE), a total of 514 patients with primary VSCC treated between 1996 - 2018 were evaluated, 21 of whom underwent pelvic LAE. In both cohorts, around 80% of the patients who underwent pelvic LAE were inguinally node-positive, with a median number of three affected groin lymph nodes. There were no cases of pelvic lymph node metastasis without inguinal lymph node metastasis in either of the two cohorts. Between 33 - 35% of the inguinal node-positive patients also had pelvic lymph node metastasis; the median number of affected groin lymph nodes in these patients was high (> 4), and the maximum median diameter of the largest inguinal metastasis was > 40 mm in both cohorts. Pelvic lymph node staging and pelvic radiotherapy is therefore probably not necessary for the majority of node-positive patients with VSCC, as the relevant risk of pelvic lymph node involvement was primarily found in node-positive patients with high-grade disease. More, ideally prospective data collections are necessary to validate the relation between inguinal and pelvic lymph node involvement.

U2 - 10.1055/a-1120-0138

DO - 10.1055/a-1120-0138

M3 - SCORING: Journal article

C2 - 33293730

VL - 80

SP - 1221

EP - 1228

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 12

ER -